Literature DB >> 16861662

Additional conjugation methods and immunogenicity of Bacillus anthracis poly-gamma-D-glutamic acid-protein conjugates.

Joanna Kubler-Kielb1, Teh-Yung Liu, Christopher Mocca, Fathy Majadly, John B Robbins, Rachel Schneerson.   

Abstract

The capsule of Bacillus anthracis, composed of poly-gamma-d-glutamic acid (gammaDPGA), is an essential virulence factor of B. anthracis. The capsule inhibits innate host defense through its antiphagocytic action. gammaDPGA is a poor immunogen, but when covalently bound to a carrier protein, it elicits serum antibodies. To identify the optimal construct for clinical use, synthetic gammaDPGAs of different lengths were bound to carrier proteins at different densities. The advantages of the synthetic over the natural polypeptide are the homogeneous chain length and end groups, allowing conjugates to be accurately characterized and standardized and their chemical compositions to be related to their immunogenicities. In the present study, we evaluated, in addition to methods reported by us, hydrazone, oxime, and thioether linkages between gammaDPGA and several proteins, including bovine serum albumin, recombinant Pseudomonas aeruginosa exotoxin A, recombinant B. anthracis protective antigen (rPA), and tetanus toxoid (TT). The effects of the dosage and formulation on the immunogenicities of the conjugates were evaluated in mice. All conjugates were immunogenic. The optimal gammaDPGA chain length of 10 to 15 amino acids and the density, an average of 15 mol gammaDPGA per mol of protein, were confirmed. The thioether bond was the optimal linkage type, and TT and rPA were the best carriers. The optimal dosage was 1.2 to 2.5 microg of gammaDPGA per mouse, and adsorption of the conjugates onto aluminum hydroxide significantly increased the antibody response to the protein with a lesser effect on anti-gammaDPGA levels.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16861662      PMCID: PMC1539631          DOI: 10.1128/IAI.00315-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

Review 1.  Human anthrax in India: urgent need for effective prevention.

Authors:  A Kumar; R Kanungo; S Bhattacharya; S Badrinath; T K Dutta; R P Swaminathan
Journal:  J Commun Dis       Date:  2000-12

2.  A new method for conjugation of carbohydrates to proteins using an aminooxy-thiol heterobifunctional linker.

Authors:  Joanna Kubler-Kielb; Vince Pozsgay
Journal:  J Org Chem       Date:  2005-08-19       Impact factor: 4.354

3.  Production, recovery and immunogenicity of the protective antigen from a recombinant strain of Bacillus anthracis.

Authors:  D M Ramirez; S H Leppla; R Schneerson; J Shiloach
Journal:  J Ind Microbiol Biotechnol       Date:  2002-04       Impact factor: 3.346

4.  Human anthrax associated with an epizootic among livestock--North Dakota, 2000.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2001-08-17       Impact factor: 17.586

5.  Anthrax capsule vaccine protects against experimental infection.

Authors:  Donald J Chabot; Angelo Scorpio; Steven A Tobery; Stephen F Little; Sarah L Norris; Arthur M Friedlander
Journal:  Vaccine       Date:  2004-11-15       Impact factor: 3.641

6.  Poly(gamma-D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine.

Authors:  Rachel Schneerson; Joanna Kubler-Kielb; Teh-Yung Liu; Zhong-Dong Dai; Stephen H Leppla; Alfred Yergey; Peter Backlund; Joseph Shiloach; Fathy Majadly; John B Robbins
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-11       Impact factor: 11.205

7.  Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine.

Authors:  S F Little; B E Ivins; P F Fellows; M L M Pitt; S L W Norris; G P Andrews
Journal:  Vaccine       Date:  2004-01-02       Impact factor: 3.641

8.  Anthrax in adults and children: a review of 132 cases in Turkey.

Authors:  A Kaya; M A Tasyaran; S Erol; Z Ozkurt; B Ozkan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-04-12       Impact factor: 3.267

9.  Immunogenicity in a mouse model of a conjugate vaccine made with a synthetic single repeating unit of type 14 pneumococcal polysaccharide coupled to CRM197.

Authors:  Fatme Mawas; Jutta Niggemann; Christopher Jones; Michael J Corbel; Johannis P Kamerling; Johannes F G Vliegenthart
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

10.  Induction of opsonic antibodies to the gamma-D-glutamic acid capsule of Bacillus anthracis by immunization with a synthetic peptide-carrier protein conjugate.

Authors:  Taia T Wang; Patricia F Fellows; Terrance J Leighton; Alexander H Lucas
Journal:  FEMS Immunol Med Microbiol       Date:  2004-04-09
View more
  6 in total

1.  Sortase-conjugation generates a capsule vaccine that protects guinea pigs against Bacillus anthracis.

Authors:  Gabriella Garufi; Ya-Ting Wang; So-Young Oh; Hannah Maier; Dominique M Missiakas; Olaf Schneewind
Journal:  Vaccine       Date:  2012-03-23       Impact factor: 3.641

2.  An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia.

Authors:  M Pravetoni; M Le Naour; T M Harmon; A M Tucker; P S Portoghese; P R Pentel
Journal:  J Pharmacol Exp Ther       Date:  2012-01-18       Impact factor: 4.030

3.  A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge.

Authors:  S D Klas; C R Petrie; S J Warwood; M S Williams; C L Olds; J P Stenz; A M Cheff; M Hinchcliffe; C Richardson; S Wimer
Journal:  Vaccine       Date:  2008-08-12       Impact factor: 3.641

4.  Saccharide/protein conjugate vaccines for Bordetella species: preparation of saccharide, development of new conjugation procedures, and physico-chemical and immunological characterization of the conjugates.

Authors:  Joanna Kubler-Kielb; Evgeny Vinogradov; Gil Ben-Menachem; Vince Pozsgay; John B Robbins; Rachel Schneerson
Journal:  Vaccine       Date:  2008-05-20       Impact factor: 3.641

5.  Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25.

Authors:  Joanna Kubler-Kielb; Fathy Majadly; Yimin Wu; David L Narum; Chunyan Guo; Louis H Miller; Joseph Shiloach; John B Robbins; Rachel Schneerson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-26       Impact factor: 12.779

6.  Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates.

Authors:  Feng Qian; Yimin Wu; Olga Muratova; Hong Zhou; Gelu Dobrescu; Peter Duggan; Lambert Lynn; Guanhong Song; Yanling Zhang; Karine Reiter; Nicholas MacDonald; David L Narum; Carole A Long; Louis H Miller; Allan Saul; Gregory E D Mullen
Journal:  Vaccine       Date:  2007-03-13       Impact factor: 4.169

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.